Retatrutide Phase 3 TRIUMPH-2 Trial Published in The Lancet

On October 10, 2026, a new publication appeared in The Lancet (London, England) detailing a trial of retatrutide. The publication is titled "Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial." This entry reports the trial as a phase 3 study involving adults with obesity and type 2 diabetes. The study design described is double-blind, parallel-group, randomised, and placebo-controlled. No specific results, outcomes, or efficacy data were included in the information provided for this entry. This brief does not summarize or interpret any findings beyond confirming that the publication exists and identifying its title, journal, and date. Readers interested in the trial details, including methodology and any reported outcomes, should consult the original publication directly via the source link. Note that this item concerns retatrutide, while albiglutide remains a separate compound currently categorized under unapproved research status. For broader context on related compounds and their current status, readers can refer to the compound overview page.